company background image
A334970 logo

Prestige Biologics KOSDAQ:A334970 Stock Report

Last Price

₩4.68k

Market Cap

₩362.3b

7D

-8.2%

1Y

8.1%

Updated

25 Dec, 2024

Data

Company Financials

Prestige Biologics Co., Ltd.

KOSDAQ:A334970 Stock Report

Market Cap: ₩362.3b

A334970 Stock Overview

Specializes in the development and production of biologic agents and biosimilars. More details

A334970 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Prestige Biologics Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Prestige Biologics
Historical stock prices
Current Share Price₩4,680.00
52 Week High₩7,830.00
52 Week Low₩3,850.00
Beta1.1
1 Month Change-12.03%
3 Month Change-23.15%
1 Year Change8.08%
3 Year Change-51.40%
5 Year Changen/a
Change since IPO-67.27%

Recent News & Updates

Recent updates

Shareholder Returns

A334970KR BiotechsKR Market
7D-8.2%-1.2%-0.9%
1Y8.1%16.3%-9.0%

Return vs Industry: A334970 underperformed the KR Biotechs industry which returned 16.3% over the past year.

Return vs Market: A334970 exceeded the KR Market which returned -9% over the past year.

Price Volatility

Is A334970's price volatile compared to industry and market?
A334970 volatility
A334970 Average Weekly Movement9.5%
Biotechs Industry Average Movement8.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A334970's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A334970's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/an/apbpharma.co.kr

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd.

Prestige Biologics Co., Ltd. Fundamentals Summary

How do Prestige Biologics's earnings and revenue compare to its market cap?
A334970 fundamental statistics
Market cap₩362.31b
Earnings (TTM)-₩25.45b
Revenue (TTM)₩1.60b

226.9x

P/S Ratio

-14.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A334970 income statement (TTM)
Revenue₩1.60b
Cost of Revenue₩16.07b
Gross Profit-₩14.47b
Other Expenses₩10.98b
Earnings-₩25.45b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-328.69
Gross Margin-906.16%
Net Profit Margin-1,593.60%
Debt/Equity Ratio67.8%

How did A334970 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prestige Biologics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution